The Global Infertility Drugs Market size is expected to reach $4.8 billion by 2028, rising at a market growth of 6.2 % CAGR during the forecast period.
Medicines used to cure infertility and improve a person"s reproductive health are referred to as infertility drugs. They may be ingested or administered intravenously. Gonadotrophins, aromatase inhibitors, selective oestrogen receptor modulators (SERMs), biguanides, dopamine agonists, ovulatory stimulants, and tricyclic antidepressants are a few of the regularly prescribed infertility medications.
Women function by promoting ovulation and ovarian follicle formation, while males support the recovery of testosterone levels and enhance the quality of sperm to promote conception. Infertility medications have been more popular among couples who are not able to conceive current history. The market participants are working to introduce cutting-edge medications for the treatment of infertility.
For example, major firms like Oxolife are now working on the development of the first-in-class product candidate, OXO-001, which enhances the binding to the uterine endometrium"s inner lining in order to optimize the embryo implantation process. The creation of such items fills a medical necessity that affects women throughout the globe who undertake assisted reproduction because there is no replacement to enhance the endometrium"s circumstances for embryo implantation.
The development of the market may be adversely affected by the availability of potent substitutes for drugs and the rising rate of their adoption. Over 2.5 million IVF operations would reportedly be carried out yearly globally in November 2021, according to a study that was published in the journal Reproductive Biomedicine. Many IVF treatments are fully funded in the majority of European nations. As a result, throughout the projection period, the danger of replacements is anticipated to be significant.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co. and Mankind Pharma Ltd.
Medicines used to cure infertility and improve a person"s reproductive health are referred to as infertility drugs. They may be ingested or administered intravenously. Gonadotrophins, aromatase inhibitors, selective oestrogen receptor modulators (SERMs), biguanides, dopamine agonists, ovulatory stimulants, and tricyclic antidepressants are a few of the regularly prescribed infertility medications.
Women function by promoting ovulation and ovarian follicle formation, while males support the recovery of testosterone levels and enhance the quality of sperm to promote conception. Infertility medications have been more popular among couples who are not able to conceive current history. The market participants are working to introduce cutting-edge medications for the treatment of infertility.
For example, major firms like Oxolife are now working on the development of the first-in-class product candidate, OXO-001, which enhances the binding to the uterine endometrium"s inner lining in order to optimize the embryo implantation process. The creation of such items fills a medical necessity that affects women throughout the globe who undertake assisted reproduction because there is no replacement to enhance the endometrium"s circumstances for embryo implantation.
The development of the market may be adversely affected by the availability of potent substitutes for drugs and the rising rate of their adoption. Over 2.5 million IVF operations would reportedly be carried out yearly globally in November 2021, according to a study that was published in the journal Reproductive Biomedicine. Many IVF treatments are fully funded in the majority of European nations. As a result, throughout the projection period, the danger of replacements is anticipated to be significant.
COVID-19 Impact Analysis
The market was negatively affected by the COVID-19 pandemic. The market for infertility medications was negatively impacted by the supply chain disruption caused by COVID-19 and the delay in the delivery of crucial goods needed for infertility drug manufacturing. Additionally, the global stoppage or postponement of reproductive treatments during COVID-19 hampered the market"s expansion. During April 2020 and March 2022, the number of patients seeking infertility treatments at 228 hospitals across 48 states decreased by 83%. The American Society for Reproductive Medicines (ASRM) issued a directive to stop all diagnostic and therapeutic operations, including infertility, in March 2020.Market Growth Factors
Factors Increasing Infertility Cases in Men and Women
The growing prevalence of infertility or the difficulty of bringing a baby to term throughout the world is what fuels the market for infertility medications. Infertility may be brought on by a number of illnesses that affect both men and women, including diabetes, cystic fibrosis, testicular failure, hormonal imbalances, menopausal disorders, urinary tract infections, pelvic inflammatory disease (PID), endometriosis, ovarian cysts, among others. Smoking, using anabolic steroids, stress, obesity, and other poor lifestyle choices are to blame for the rise in instances of these problems, which also contributes to the need for infertility medications.Increasing Research and Development for Better Treatment
Due to growing research and development studies for more efficient treatments to induce conception and deliver live babies, the market for infertility medications is anticipated to expand significantly. For example, a group of researchers at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) of the National Institutes of Health (NIH) discovered in 2014 that women treated with letrozole have higher rates of ovulation and live births than women treated with the standard medication, Clomiphene.Market Restraining Factor
Possibility of any adverse effects
Whether women choose to have intrauterine insemination (IUI), in vitro fertilization (IVF), or other types of treatments, fertility medications are a critical component of the treatment process. These drugs are used to encourage the body to produce certain hormones and to balance the levels of other substances. Gonadotropins are administered to encourage a woman"s eggs to release once they are mature. The possibility of multiple births, including twins and triplets, ovarian hyperstimulation syndrome (OHSS), and ectopic pregnancy (eggs implanting on the fallopian tubes rather than in the uterus), are all possible adverse effects of this (enlargement of the ovaries).End-user Outlook
Based on end-user, the infertility drugs Market is divided into Men and Women. The women segment led the market with the largest revenue share in the market during 2021. This dominance may be related to the widespread accessibility of female infertility medications. In the United States, 11% of women and 9% of males of reproductive age have infertility, according to the U.S. Department of Health and Human Services.
Distribution Channel Outlook
Based on distribution channel, the Infertility Drugs Market is divided into Hospital Pharmacy, Specialty & Retail Pharmacy, and Online Pharmacy. Online Pharmacy generated the significant revenue share during 2021 in the market. The emergence of online clinical chains, which provide patients with scheduled medication deliveries and promote patient discretion owing to the social stigma connected with the ailment, might be credited with the segment"s rise.Drug Class Outlook
Based on drug class, the infertility drugs market is classified into Gonadotropins, Aromatase Inhibitors, Selective Estrogen Receptor Modulators (SERMs), Dopamine Agonists, and Others. The gonadotropins segment accounted for the highest revenue share in the market in 2021. This may be ascribed to the expensive nature of the goods and the greater efficacy"s effect on increasing consumption. The gonadotropins Gonal-F, Follitism, Menopur, and Bravelle, are some of the most often prescribed for treating infertility in patients.Regional Outlook
Based on region, the Infertility Drugs Market is divided into North America, Europe, Asia Pacific, and LAMEA. North America dominated the Infertility Drugs Market in 2021 with the highest revenue share due to the introduction and quick adoption of several infertility medications. It is anticipated that rising infertility research activity in the area would provide additional job possibilities. For instance, Ferring B.V. and Igenomix signed a four-year research agreement in June 2020 to collaborate on the development of innovative therapeutic solutions for the care of patients with disorders associated with pregnancy.The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Bayer AG, Novartis AG, Merck & Co., Inc., Pfizer, Inc., Teva Pharmaceuticals Industries Ltd., Sanofi S.A., Ferring Holdings SA, Organon & Co. and Mankind Pharma Ltd.
Scope of the Study
By End-user
- Women
- Men
By Distribution Channel
- Hospital Pharmacy
- Specialty & Retail Pharmacy
- Online Pharmacy
By Drug Class
- Gonadotropins
- Aromatase Inhibitors
- Selective Estrogen Receptor Modulators (SERMs)
- Dopamine Agonists
- Others
By Geography
- North America
- US
- Canada
- Mexico
- Rest of North America
- Europe
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Singapore
- Malaysia
- Rest of Asia Pacific
- LAMEA
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Abbott Laboratories
- Bayer AG
- Novartis AG
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Ferring Holdings SA
- Organon & Co.
- Mankind Pharma Ltd.
Unique Offerings
- Exhaustive coverage
- The highest number of market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Infertility Drugs Market, by End User
1.4.2 Global Infertility Drugs Market, by Distribution Channel
1.4.3 Global Infertility Drugs Market, by Drug Class
1.4.4 Global Infertility Drugs Market, by Geography
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition and Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Global Infertility Drugs Market by End-user
3.1 Global Women Market by Region
3.2 Global Men Market by Region
Chapter 4. Global Infertility Drugs Market by Distribution Channel
4.1 Global Hospital Pharmacy Market by Region
4.2 Global Specialty & Retail Pharmacy Market by Region
4.3 Global Online Pharmacy Market by Region
Chapter 5. Global Infertility Drugs Market by Drug Class
5.1 Global Gonadotropins Market by Region
5.2 Global Aromatase Inhibitors Market by Region
5.3 Global Selective Estrogen Receptor Modulators (SERMs) Market by Region
5.4 Global Dopamine Agonists Market by Region
5.5 Global Others Market by Region
Chapter 6. Global Infertility Drugs Market by Region
6.1 North America Infertility Drugs Market
6.1.1 North America Infertility Drugs Market by End-user
6.1.1.1 North America Women Market by Country
6.1.1.2 North America Men Market by Country
6.1.2 North America Infertility Drugs Market by Distribution Channel
6.1.2.1 North America Hospital Pharmacy Market by Country
6.1.2.2 North America Specialty & Retail Pharmacy Market by Country
6.1.2.3 North America Online Pharmacy Market by Country
6.1.3 North America Infertility Drugs Market by Drug Class
6.1.3.1 North America Gonadotropins Market by Country
6.1.3.2 North America Aromatase Inhibitors Market by Country
6.1.3.3 North America Selective Estrogen Receptor Modulators (SERMs) Market by Country
6.1.3.4 North America Dopamine Agonists Market by Country
6.1.3.5 North America Others Market by Country
6.1.4 North America Infertility Drugs Market by Country
6.1.4.1 US Infertility Drugs Market
6.1.4.1.1 US Infertility Drugs Market by End-user
6.1.4.1.2 US Infertility Drugs Market by Distribution Channel
6.1.4.1.3 US Infertility Drugs Market by Drug Class
6.1.4.2 Canada Infertility Drugs Market
6.1.4.2.1 Canada Infertility Drugs Market by End-user
6.1.4.2.2 Canada Infertility Drugs Market by Distribution Channel
6.1.4.2.3 Canada Infertility Drugs Market by Drug Class
6.1.4.3 Mexico Infertility Drugs Market
6.1.4.3.1 Mexico Infertility Drugs Market by End-user
6.1.4.3.2 Mexico Infertility Drugs Market by Distribution Channel
6.1.4.3.3 Mexico Infertility Drugs Market by Drug Class
6.1.4.4 Rest of North America Infertility Drugs Market
6.1.4.4.1 Rest of North America Infertility Drugs Market by End-user
6.1.4.4.2 Rest of North America Infertility Drugs Market by Distribution Channel
6.1.4.4.3 Rest of North America Infertility Drugs Market by Drug Class
6.2 Europe Infertility Drugs Market
6.2.1 Europe Infertility Drugs Market by End-user
6.2.1.1 Europe Women Market by Country
6.2.1.2 Europe Men Market by Country
6.2.2 Europe Infertility Drugs Market by Distribution Channel
6.2.2.1 Europe Hospital Pharmacy Market by Country
6.2.2.2 Europe Specialty & Retail Pharmacy Market by Country
6.2.2.3 Europe Online Pharmacy Market by Country
6.2.3 Europe Infertility Drugs Market by Drug Class
6.2.3.1 Europe Gonadotropins Market by Country
6.2.3.2 Europe Aromatase Inhibitors Market by Country
6.2.3.3 Europe Selective Estrogen Receptor Modulators (SERMs) Market by Country
6.2.3.4 Europe Dopamine Agonists Market by Country
6.2.3.5 Europe Others Market by Country
6.2.4 Europe Infertility Drugs Market by Country
6.2.4.1 Germany Infertility Drugs Market
6.2.4.1.1 Germany Infertility Drugs Market by End-user
6.2.4.1.2 Germany Infertility Drugs Market by Distribution Channel
6.2.4.1.3 Germany Infertility Drugs Market by Drug Class
6.2.4.2 UK Infertility Drugs Market
6.2.4.2.1 UK Infertility Drugs Market by End-user
6.2.4.2.2 UK Infertility Drugs Market by Distribution Channel
6.2.4.2.3 UK Infertility Drugs Market by Drug Class
6.2.4.3 France Infertility Drugs Market
6.2.4.3.1 France Infertility Drugs Market by End-user
6.2.4.3.2 France Infertility Drugs Market by Distribution Channel
6.2.4.3.3 France Infertility Drugs Market by Drug Class
6.2.4.4 Russia Infertility Drugs Market
6.2.4.4.1 Russia Infertility Drugs Market by End-user
6.2.4.4.2 Russia Infertility Drugs Market by Distribution Channel
6.2.4.4.3 Russia Infertility Drugs Market by Drug Class
6.2.4.5 Spain Infertility Drugs Market
6.2.4.5.1 Spain Infertility Drugs Market by End-user
6.2.4.5.2 Spain Infertility Drugs Market by Distribution Channel
6.2.4.5.3 Spain Infertility Drugs Market by Drug Class
6.2.4.6 Italy Infertility Drugs Market
6.2.4.6.1 Italy Infertility Drugs Market by End-user
6.2.4.6.2 Italy Infertility Drugs Market by Distribution Channel
6.2.4.6.3 Italy Infertility Drugs Market by Drug Class
6.2.4.7 Rest of Europe Infertility Drugs Market
6.2.4.7.1 Rest of Europe Infertility Drugs Market by End-user
6.2.4.7.2 Rest of Europe Infertility Drugs Market by Distribution Channel
6.2.4.7.3 Rest of Europe Infertility Drugs Market by Drug Class
6.3 Asia Pacific Infertility Drugs Market
6.3.1 Asia Pacific Infertility Drugs Market by End-user
6.3.1.1 Asia Pacific Women Market by Country
6.3.1.2 Asia Pacific Men Market by Country
6.3.2 Asia Pacific Infertility Drugs Market by Distribution Channel
6.3.2.1 Asia Pacific Hospital Pharmacy Market by Country
6.3.2.2 Asia Pacific Specialty & Retail Pharmacy Market by Country
6.3.2.3 Asia Pacific Online Pharmacy Market by Country
6.3.3 Asia Pacific Infertility Drugs Market by Drug Class
6.3.3.1 Asia Pacific Gonadotropins Market by Country
6.3.3.2 Asia Pacific Aromatase Inhibitors Market by Country
6.3.3.3 Asia Pacific Selective Estrogen Receptor Modulators (SERMs) Market by Country
6.3.3.4 Asia Pacific Dopamine Agonists Market by Country
6.3.3.5 Asia Pacific Others Market by Country
6.3.4 Asia Pacific Infertility Drugs Market by Country
6.3.4.1 China Infertility Drugs Market
6.3.4.1.1 China Infertility Drugs Market by End-user
6.3.4.1.2 China Infertility Drugs Market by Distribution Channel
6.3.4.1.3 China Infertility Drugs Market by Drug Class
6.3.4.2 Japan Infertility Drugs Market
6.3.4.2.1 Japan Infertility Drugs Market by End-user
6.3.4.2.2 Japan Infertility Drugs Market by Distribution Channel
6.3.4.2.3 Japan Infertility Drugs Market by Drug Class
6.3.4.3 India Infertility Drugs Market
6.3.4.3.1 India Infertility Drugs Market by End-user
6.3.4.3.2 India Infertility Drugs Market by Distribution Channel
6.3.4.3.3 India Infertility Drugs Market by Drug Class
6.3.4.4 South Korea Infertility Drugs Market
6.3.4.4.1 South Korea Infertility Drugs Market by End-user
6.3.4.4.2 South Korea Infertility Drugs Market by Distribution Channel
6.3.4.4.3 South Korea Infertility Drugs Market by Drug Class
6.3.4.5 Singapore Infertility Drugs Market
6.3.4.5.1 Singapore Infertility Drugs Market by End-user
6.3.4.5.2 Singapore Infertility Drugs Market by Distribution Channel
6.3.4.5.3 Singapore Infertility Drugs Market by Drug Class
6.3.4.6 Malaysia Infertility Drugs Market
6.3.4.6.1 Malaysia Infertility Drugs Market by End-user
6.3.4.6.2 Malaysia Infertility Drugs Market by Distribution Channel
6.3.4.6.3 Malaysia Infertility Drugs Market by Drug Class
6.3.4.7 Rest of Asia Pacific Infertility Drugs Market
6.3.4.7.1 Rest of Asia Pacific Infertility Drugs Market by End-user
6.3.4.7.2 Rest of Asia Pacific Infertility Drugs Market by Distribution Channel
6.3.4.7.3 Rest of Asia Pacific Infertility Drugs Market by Drug Class
6.4 LAMEA Infertility Drugs Market
6.4.1 LAMEA Infertility Drugs Market by End-user
6.4.1.1 LAMEA Women Market by Country
6.4.1.2 LAMEA Men Market by Country
6.4.2 LAMEA Infertility Drugs Market by Distribution Channel
6.4.2.1 LAMEA Hospital Pharmacy Market by Country
6.4.2.2 LAMEA Specialty & Retail Pharmacy Market by Country
6.4.2.3 LAMEA Online Pharmacy Market by Country
6.4.3 LAMEA Infertility Drugs Market by Drug Class
6.4.3.1 LAMEA Gonadotropins Market by Country
6.4.3.2 LAMEA Aromatase Inhibitors Market by Country
6.4.3.3 LAMEA Selective Estrogen Receptor Modulators (SERMs) Market by Country
6.4.3.4 LAMEA Dopamine Agonists Market by Country
6.4.3.5 LAMEA Others Market by Country
6.4.4 LAMEA Infertility Drugs Market by Country
6.4.4.1 Brazil Infertility Drugs Market
6.4.4.1.1 Brazil Infertility Drugs Market by End-user
6.4.4.1.2 Brazil Infertility Drugs Market by Distribution Channel
6.4.4.1.3 Brazil Infertility Drugs Market by Drug Class
6.4.4.2 Argentina Infertility Drugs Market
6.4.4.2.1 Argentina Infertility Drugs Market by End-user
6.4.4.2.2 Argentina Infertility Drugs Market by Distribution Channel
6.4.4.2.3 Argentina Infertility Drugs Market by Drug Class
6.4.4.3 UAE Infertility Drugs Market
6.4.4.3.1 UAE Infertility Drugs Market by End-user
6.4.4.3.2 UAE Infertility Drugs Market by Distribution Channel
6.4.4.3.3 UAE Infertility Drugs Market by Drug Class
6.4.4.4 Saudi Arabia Infertility Drugs Market
6.4.4.4.1 Saudi Arabia Infertility Drugs Market by End-user
6.4.4.4.2 Saudi Arabia Infertility Drugs Market by Distribution Channel
6.4.4.4.3 Saudi Arabia Infertility Drugs Market by Drug Class
6.4.4.5 South Africa Infertility Drugs Market
6.4.4.5.1 South Africa Infertility Drugs Market by End-user
6.4.4.5.2 South Africa Infertility Drugs Market by Distribution Channel
6.4.4.5.3 South Africa Infertility Drugs Market by Drug Class
6.4.4.6 Nigeria Infertility Drugs Market
6.4.4.6.1 Nigeria Infertility Drugs Market by End-user
6.4.4.6.2 Nigeria Infertility Drugs Market by Distribution Channel
6.4.4.6.3 Nigeria Infertility Drugs Market by Drug Class
6.4.4.7 Rest of LAMEA Infertility Drugs Market
6.4.4.7.1 Rest of LAMEA Infertility Drugs Market by End-user
6.4.4.7.2 Rest of LAMEA Infertility Drugs Market by Distribution Channel
6.4.4.7.3 Rest of LAMEA Infertility Drugs Market by Drug Class
Chapter 7. Company Profiles
7.1 Abbott Laboratories
7.1.1 Company Overview
7.1.2 Financial Analysis
7.1.3 Segmental and Regional Analysis
7.1.4 Research & Development Expense
7.1.5 SWOT Analysis
7.2 Bayer AG
7.2.1 Company Overview
7.2.2 Financial Analysis
7.2.3 Segmental and Regional Analysis
7.2.4 Research & Development Expense
7.2.5 Recent strategies and developments:
7.2.5.1 Partnerships, Collaborations, and Agreements:
7.2.5.2 Acquisition and Mergers:
7.3 Novartis AG
7.3.1 Company Overview
7.3.2 Financial Analysis
7.3.3 Segmental and Regional Analysis
7.3.4 Research & Development Expense
7.4 Merck & Co., Inc.
7.4.1 Company Overview
7.4.2 Financial Analysis
7.4.3 Segmental and Regional Analysis
7.4.4 Research & Development Expenses
7.5 Pfizer, Inc.
7.5.1 Company Overview
7.5.2 Financial Analysis
7.5.3 Regional & Segmental Analysis
7.5.4 Research & Development Expense
7.5.5 Recent strategies and developments:
7.5.5.1 Partnerships, Collaborations, and Agreements:
7.6 Teva Pharmaceutical Industries Ltd.
7.6.1 Company Overview
7.6.2 Financial Analysis
7.6.3 Regional Analysis
7.6.4 Research & Development Expenses
7.7 Sanofi S.A.
7.7.1 Company Overview
7.7.2 Financial Analysis
7.7.3 Segmental and Regional Analysis
7.7.4 Research & Development Expense
7.8 Ferring Holdings SA
7.8.1 Company Overview
7.8.2 Financial Analysis
7.8.3 Regional Analysis
7.8.4 Research and Development Expense
7.8.5 Recent strategies and developments:
7.8.5.1 Partnerships, Collaborations, and Agreements:
7.9 Organon & Co.
7.9.1 Company Overview
7.9.2 Financial Analysis
7.9.3 Regional Analysis
7.9.4 Research & Development Expenses
7.10. Mankind Pharma Ltd.
7.10.1 Company Overview
7.10.2 Recent strategies and developments:
7.10.2.1 Product Launches and Product Expansions:
Companies Mentioned
- Abbott Laboratories
- Bayer AG
- Novartis AG
- Merck & Co., Inc.
- Pfizer, Inc.
- Teva Pharmaceuticals Industries Ltd.
- Sanofi S.A.
- Ferring Holdings SA
- Organon & Co.
- Mankind Pharma Ltd.
Methodology
LOADING...
